180 Life Sciences: Leading Research into Solving one of the World’s Largest Drivers of Disease: Inflammation
Dr. Jim Woody, CEO and Director of 180 Life Sciences, a clinical stage biotechnology company headquartered in Palo Alto, California, focused on the development of therapeutics for unmet medical needs in chronic pain, inflammation and fibrosis joins eHealth Radio and the Health News Channel.
Listen to interview with host Eric Michaels and guest Dr. Jim Woody discuss the following:
Please tell us a bit about your background, how 180 Life Sciences was founded and what the mission is behind the company.
The company's pipeline includes three families of novel drugs that address significant market opportunities in inflammation, fibrosis and pain. Can you share a brief overview of each?
What solutions has 180 Life Sciences developed within its anti-TNF program to address the pitfalls in current standards of care for diseases like fibrosis, POCD, or frozen shoulder?
How is 180 Life Sciences meeting the unmet need of patients suffering from inflammatory diseases differently than industry peers?
What can you share about the company's vision for safer pain management and the SCAs program?
Looking ahead, what exciting advances do you think are on the horizon for 180 Life Sciences?
JAMES N. WOODY, M.D., Ph.D. is a Pediatric Immunologist that has managed many biotech companies, and invented both technologies and drugs that have been highly beneficial to patients.
Dr. Woody has served as the CEO of 180 Life Sciences since July 2020, and as a director of 180 since September 2020. Dr. Woody was a founder and served as Chairman of the Board of Directors for Viracta Pharmaceuticals, a lymphoma therapeutic company (July 2014 to December 2020). With the company undergoing a reverse merger into a public company, he resigned his Board member position and continues as a Board observer. He served as a General Partner of Latterell Venture Partners (February 2006 to December 2019) then moved to a Venture Partner position, for the one remaining LVP legacy company, PerceptiMed, a Pharmacy management company, where he continues to serve on the Board as they plan their IPO. He served as an interim CEO for MaraBio Systems Inc., a startup autism diagnostic company, from November 2018 to December 2022, when a new full time CEO was selected. He continues to serve as Vice Chairman, on the Board of Directors. He also serves as Chairman of the Board for Enosi Life Sciences, a next generation TNF inhibitor company, which position he has held since July 2020. He served as a Board member of IntegenX Inc. (2012 to 2018), and Neuraltus Pharmaceuticals, Inc. (February 2009 to December 2019).